MRPS22

Across TCGA pan-cancer cohorts, MRPS22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPS22 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MRPS22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MRPS22 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, GBM, and PDAC are the cancer types where MRPS22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	1.000	0.485	.001	29	view →
GBM	OS	Quartile	All	0.602	0.226	.016	7	view →
PDAC	OS	Tertile	IV	0.443	0.973	.024	6	view →
LUAD	DFS	Tertile	All	0.500	0.874	.029	4	view →
CCRCC	OS	Quartile	II,III,IV	0.894	0.579	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRPS22–LSCC (DFS)

Open the LSCC breakdown →